Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Haemodialysis
Interventions
DRUG

Heparin 2,400 IU /ml Cutaneous Spray

Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.

DRUG

Placebo Cutaneous Spray

Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.

Trial Locations (3)

1090

Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse, Medizinische Universität Wien, Vienna

1160

6. Medizinische Abteilung mit Nephrologie und Dialyse, Wilhelminenspital Wien, Vienna

4020

Krankenhaus der Elisabethinen Linz, Linz

All Listed Sponsors
lead

Cyathus Exquirere Pharmaforschungsgmbh

INDUSTRY